Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Karl H. Beyer"'
Autor:
Karl H. Beyer, Elliot S. Vesell
Publikováno v:
Toxicology. 144:5-11
Herein are described the development and certain properties of a new drug, pyrazinoylguanidine (PZG), intended for use as an adjunct in the treatment of hypertensive patients with type 2 diabetes, formerly called noninsulin dependent diabetes mellitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e683389eeb103aad3840e0d0a731bf13
https://doi.org/10.1016/s0300-483x(99)00213-9
https://doi.org/10.1016/s0300-483x(99)00213-9
Autor:
Karl H. Beyer, Elliot S. Vesell
Publikováno v:
Pharmacology. 58:140-146
In a three-phase study, single oral doses of placebo, followed in 1 week by pyrazinoylguanidine (PZG; 900 mg), followed in 3 weeks by pyrazinoic acid (PZA; 300 mg) were given to 8 normal male subjects. Blood analyses performed 0, 2 and 4 h after admi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75c35e8825b66cc53b4dc8c695a06580
https://doi.org/10.1159/000028276
https://doi.org/10.1159/000028276
Publikováno v:
Pharmacology. 54:241-255
This study was designed to determine whether pyrazinoylguanidine (PZG) can attenuate diabetic nephropathy in streptozotocin (STZ)-induced diabetic rats. Diabetes was induced within 1 week after a single intraperitoneal dose of STZ (45 mg/kg in 0.05 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e68fa9c85ef98cb737fc9a7a87f123e4
https://doi.org/10.1159/000139492
https://doi.org/10.1159/000139492
Publikováno v:
Pharmacology. 52:145-152
Pyrazinoylguanidine (PZG) is a new antihyperglycemic, antihyperlipidemic drug. The current study reports on the development of an animal model in which the favorable metabolic effects of PZG, previously described in diabetic patients, could be reprod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0eb08d7d5a06bc391cd63b1ecec3e4
https://doi.org/10.1159/000139378
https://doi.org/10.1159/000139378
Publikováno v:
Pharmacology. 53:211-218
In isolated rat adipocytes stimulated with theophylline (1 mmol/l), pyrazinoylguanidine (PZG) downregulated both lipolysis and cyclic AMP concentrations, raising the possibility that PZG stimulates adipose insulin-sensitive phosphodiesterase. To inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::113fd7fdf3da08c1860122046f184f52
https://doi.org/10.1159/000139432
https://doi.org/10.1159/000139432
Autor:
Charles E. Chambers, Laurence M. Demers, Elliot S. Vesell, Karl H. Beyer, G. Thomas Passananti
Publikováno v:
The Journal of Clinical Pharmacology. 33:823-831
Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non-insulin-dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6604ec1173d8bf66e24ddb0cf29a9cee
https://doi.org/10.1002/j.1552-4604.1993.tb01958.x
https://doi.org/10.1002/j.1552-4604.1993.tb01958.x
Autor:
Thomas D. Ward, R. Thomas Gelarden, Jean E. Vary, Elliot S. Vesell, David W. Knutson, Karl H. Beyer
Publikováno v:
The Journal of Clinical Pharmacology. 33:554-561
A single blind crossover study with washout phases showed that pyrazinoylguanidine (PZG) reduced elevated serum concentrations of urea, triglycerides, and cholesterol in patients with renal insufficiency. Pyrazinoylguanidine was saluretic, without af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::619ae47408c4c4dd711e45245d405d1d
https://doi.org/10.1002/j.1552-4604.1993.tb04703.x
https://doi.org/10.1002/j.1552-4604.1993.tb04703.x
Publikováno v:
The American journal of physiology. 145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46f9d733540d5af54ea7940193fcf38
https://pubmed.ncbi.nlm.nih.gov/21021841
https://pubmed.ncbi.nlm.nih.gov/21021841
Publikováno v:
The American journal of physiology. 151(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b2bb4c73fffe98e9c6fca005e15e93
https://pubmed.ncbi.nlm.nih.gov/20271662
https://pubmed.ncbi.nlm.nih.gov/20271662
Publikováno v:
The American journal of physiology. 149(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b6ba3b803987ceb40c72b34486f9f95
https://pubmed.ncbi.nlm.nih.gov/20239964
https://pubmed.ncbi.nlm.nih.gov/20239964